Christine Katusiime1, Walter F Schlech2, Rosalind Parkes-Ratanshi3, Joseph Sempa3, Andrew Kambugu4. 1. Prevention, Care and Treatment Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda katutina1@gmail.com. 2. Division of Infectious Diseases, Faculty of Medicine, Dalhousie University, Nova Scotia, Canada. 3. Prevention, Care and Treatment Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. 4. Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Abstract
BACKGROUND: Sexually transmitted infections (STIs) significantly increase HIV transmission. Sexually transmitted infections may be asymptomatic and therefore remain undiagnosed in HIV-positive persons. Routine screening and treatment of STIs in HIV-positive high-risk populations in sub-Saharan Africa have not been described previously. METHODS: We reviewed data from an HIV-positive high-risk population at the Infectious Diseases Institute, Makerere University, a large urban HIV clinic, between July 2011 and April 2012. Our high-risk population cohort included female sex workers, long-distance drivers, barmaids, taxi drivers, commercial motorcycle "boda-boda" riders, soldiers, police officers, prison officers, security guards, prisoners, and fishermen. RESULTS: Of 355 participants enrolled in the high-risk population's program, 21.4% were diagnosed with an STI either clinically or microbiologically. The STIs diagnosed in this population were syphilis, hepatitis B, genital herpes, human papilloma virus infection (condylomata acuminata), nongonococcal urethritis (NGU), and gonorrhea. Rates of syphilis, hepatitis B, genital herpes, condylomata acuminata, NGU, and gonorrhea were 8.5%, 7.0%, 5.4%, 1.4%, 1.4%, and 0.3%, respectively. CONCLUSION: Clinical and microbiologically diagnosed STIs were diagnosed in nearly one-fourth of the HIV-positive high-risk population. HIV care programs should note our high rates of STIs among HIV-positive high-risk populations and consider routine screening and treatment algorithms for these populations in their own settings.
BACKGROUND: Sexually transmitted infections (STIs) significantly increase HIV transmission. Sexually transmitted infections may be asymptomatic and therefore remain undiagnosed in HIV-positivepersons. Routine screening and treatment of STIs in HIV-positive high-risk populations in sub-Saharan Africa have not been described previously. METHODS: We reviewed data from an HIV-positive high-risk population at the Infectious Diseases Institute, Makerere University, a large urban HIV clinic, between July 2011 and April 2012. Our high-risk population cohort included female sex workers, long-distance drivers, barmaids, taxi drivers, commercial motorcycle "boda-boda" riders, soldiers, police officers, prison officers, security guards, prisoners, and fishermen. RESULTS: Of 355 participants enrolled in the high-risk population's program, 21.4% were diagnosed with an STI either clinically or microbiologically. The STIs diagnosed in this population were syphilis, hepatitis B, genital herpes, human papilloma virus infection (condylomata acuminata), nongonococcal urethritis (NGU), and gonorrhea. Rates of syphilis, hepatitis B, genital herpes, condylomata acuminata, NGU, and gonorrhea were 8.5%, 7.0%, 5.4%, 1.4%, 1.4%, and 0.3%, respectively. CONCLUSION: Clinical and microbiologically diagnosed STIs were diagnosed in nearly one-fourth of the HIV-positive high-risk population. HIV care programs should note our high rates of STIs among HIV-positive high-risk populations and consider routine screening and treatment algorithms for these populations in their own settings.
Authors: Faith Nawagi; Arthur Mpimbaza; John Mukisa; Patrick Serwadda; Samuel Kyalema; Daniel Kizza Journal: Afr Health Sci Date: 2016-03 Impact factor: 0.927
Authors: E Seremba; P Ocama; R Ssekitoleko; H Mayanja-Kizza; S V Adams; J Orem; E Katabira; S J Reynolds; R Nabatanzi; C Casper; W Phipps Journal: Vaccine Date: 2021-01-28 Impact factor: 3.641
Authors: Moses Muwanguzi; Henry Mark Lugobe; Elastus Ssemwanga; Allan Phillip Lule; Elizabeth Atwiine; Vincent Kirabira; Ann K Stella; Scholastic Ashaba; Godfrey Zari Rukundo Journal: BMC Public Health Date: 2021-07-31 Impact factor: 3.295